Abstract: The present invention is directed to a process for the preparation of sulfamide derivatives.

Abstract: The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from quetiapine. The invention also relates to conjugates of a quetiapine hapten and a protein.

Abstract: The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from olanzipine. The invention also relates to conjugates of an olanzipine hapten and a protein.

Abstract: Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Abstract: Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.

Abstract: Disclosed is a stereoscopic image display panel and a stereoscopic image display device including the same, which minimize the degradation of image quality due to crosstalk between left and right images discerned by a viewer, and have enhanced brightness and aperture ratio, wherein the stereoscopic image display panel comprises a first substrate including a plurality of data lines formed at certain intervals apart, a plurality of gate lines formed to intersect the data lines, and first and second pixel groups formed adjacently to each other with two adjacent gate lines therebetween; and a second substrate including a light shield layer formed at one side and other side of each of the first and second pixel groups to have different overlapped widths, and defining an open area of each of the first and second pixel groups, wherein the first and second pixel groups display different stereoscopic images, respectively.

Abstract: Disclosed is a stereoscopic image display panel and a stereoscopic image display device including the same, which minimize the degradation of image quality due to crosstalk between left and right images discerned by a viewer, and have enhanced brightness and aperture ratio, wherein the stereoscopic image display panel comprises a first substrate including a plurality of data lines formed at certain intervals apart, a plurality of gate lines formed to intersect the data lines, and first and second pixel groups formed adjacently to each other with two adjacent gate lines therebetween; and a second substrate including a light shield layer formed at one side and other side of each of the first and second pixel groups to have different overlapped widths, and defining an open area of each of the first and second pixel groups, wherein the first and second pixel groups display different stereoscopic images, respectively.

Abstract: A multi-panel display device and a method of driving the same, which can simplify a driving circuit for driving multiple flat panel display devices, thereby decreasing the fabrication cost, are disclosed. In the device configured of an alignment of multiple flat panel display devices for representing a single image, the device comprises multiple flat panel display devices, wherein each flat panel display device includes a display panel configured of a plurality of pixel regions, a data driver driving a plurality of data lines provided in the display panel, and a timing controller receiving image data and synchronization signals from an external source so as to divide the received image data, converting a signal frequency of at least one of the synchronization signals, and converting a size of the divided image data in accordance with the frequency-converted synchronization signal, thereby providing the size-converted divided image data to the data driver.

Abstract: This invention relates to compounds of formula which inhibit Factor Xa or tryptase, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa or tryptase.

Abstract: A multi-panel display device and a method of driving the same, which can simplify a driving circuit for driving multiple flat panel display devices, thereby decreasing the fabrication cost, are disclosed. In the device configured of an alignment of multiple flat panel display devices for representing a single image, the device comprises multiple flat panel display devices, wherein each flat panel display device includes a display panel configured of a plurality of pixel regions, a data driver driving a plurality of data lines provided in the display panel, and a timing controller receiving image data and synchronization signals from an external source so as to divide the received image data, converting a signal frequency of at least one of the synchronization signals, and converting a size of the divided image data in accordance with the frequency-converted synchronization signal, thereby providing the size-converted divided image data to the data driver.

Abstract: Substituted 5,6,7,8-tetrahydroquinoline derivatives, which are C5a receptor modulators, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, immune and inflammatory diseases and conditions, are disclosed.

Abstract: The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful ?4 integrin receptor antagonists and, in particular, ?4?1 and ?4?7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.

Abstract: Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.

Abstract: Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating ?4 integrin mediated disorders. More particularly, the pyridazinone urea compounds of the present invention are ?4?7 integrin inhibitors useful for treating integrin mediated disorders.

Abstract: The present invention relates to certain novel compounds of Formula (I): methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of integrin mediated disorders.

Abstract: The invention is directed to aza-bridged-bicyclic compounds having Formula (I): and pharmaceutically acceptable salts thereof. The compounds are useful ?4 integrin receptor antagonists and, in particular, ?4?1 and ?4?7 integrin receptor antagonists. The invention is further directed to methods for use of the instant compounds for treating integrin mediated disorders including, but not limited to, inflammatory disorders, autoimmune disorders and cell-proliferative disorders, methods for preparing the compounds and methods for preparing the intermediates, derivatives and pharmaceutical compositions thereof.

Abstract: This invention relates to compounds of formula 1